RESUMO
Objective To evaluate the diagnosis and the clinical application value of serum soluble MICA protein in patients with esophageal carcinoma or cardiac carcinoma.Methods The serum sMICA was concomitantly determined by ELISA in 50 preoperative patients with esophageal carcinoma or cardiac carcinoma and 20 healthy controls.Results The level of serum sMICA in patients was significantly higher than that in controls[(322.42±9.09)pg/ml,(176.00±11.69)pg/ml](P＜0.01).In patients with TNM stage Ⅱ,Ⅲ,Ⅳ,the level of serum sMICA increased significantly in order(P＜0.05).In patients with lymph node metastasis.the level of serum sMICA was significantly higher than that without lymph node metastasis.The level of serum sMICA in patients with imbricate carcinoma was higher than patients with glandiform carcinoma.In patients with TNM stageⅢ.the level of serum sMICA after operation was significantly lower than that before operation.ConclusionSerum sMICA could be an assistant indicator for esophageal carcinoma or cardiac carcinoma.sMICA could be considered as a new tumour symbol to evaluate the biological behavior and prognosis of esophageal and cardiac carcinoma.
RESUMO
Objective To investigate a kind of new operation style aiming directly at middle and late stage cardic cancer. Methods To use the routine resection and retrograde resection simultaneusly as surgical treatment for those difficult to be exercised. Results This is no exploration case in this group. There is no case perioperation death. This method has improved the patient's epitite and quality of life (QOL)obviously. Conclusion This operation style provided a new kind of effective method for the treatment of middle and late stage cardic cancer. It set a solid foundation for improving the patient's QOL and combined treatment after the operation.